Pregnancy outcomes and neonatal outcomes after pituitary down-regulation in patients with adenomyosis receiving IVF/ICSI and FET: Results of a retrospective cohort study

International Journal of Clinical and Experimental Medicine

Volumn 9, Issue 7, 2016, Pages 14313-14320

  Guo, Song ^a   Zhang, Di ^b   Niu, Zhihong ^a   Sun, Yijuan ^c   Feng, Yun ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b JINAN MILITARY GENERAL HOSPITAL   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Adenomyosis; FET; Neonatal outcome; Pituitary down regulation; Pregnancy outcome

Indexed keywords

TRIPTORELIN;

ADENOMYOSIS; ADULT; ARTICLE; COHORT ANALYSIS; DOWN REGULATION; EMBRYO TRANSFER; FEMALE; FROZEN THAWED EMBRYO TRANSFER; HORMONE SUBSTITUTION; HUMAN; IN VITRO FERTILIZATION; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; PREGNANCY OUTCOME; RETROSPECTIVE STUDY; TRANSVAGINAL ECHOGRAPHY;

EID: 84985906587     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Carrarelli P, Yen CF, Arcuri F, Funghi L, Tosti C, Wang TH, Huang JS, Petraglia F. Myostatin, follistatin and activin type II receptors are highly expressed in adenomyosis. Fertil Steril 2015; 104: 744-52, e1.
2. Salim R, Riris S, Saab W, Abramov B, Khadum I, Serhal P. Adenomyosis reduces pregnan-cy rates in infertile women undergoing IVF. Reprod Biomed Online 2012; 25: 273-7.
3. Vercellini P, Consonni D, Dridi D, Bracco B, Frattaruolo MP, Somigliana E. Uterine adenomyosis and in vitro fertilization outcome: a systematic review and meta-analysis. Hum Reprod 2014; 29: 964-77.
4. Yan L, Ding L, Tang R, Chen ZJ. Effect of ade-nomyosis on in vitro fertilization/intracyto-plasmic sperm injection outcomes in infertile women: a retrospective cohort study. Gynecol Obstet Invest 2014; 77: 14-8.
5. Shaaban OM, Ali MK, Sabra AM, Abd El Aal DE. Levonorgestrel-releasing intrauterine system versus a low-dose combined oral contraceptive for treatment of adenomyotic uteri: a randomized clinical trial. Contraception 2015; 92: 301-7.
6. Surrey ES, Silverberg KM, Surrey MW, Sch-oolcraft WB. Effect of prolonged gonadotro-pin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis. Fertil Steril 2002; 78: 699-704.
7. Rickes D, Nickel I, Kropf S, Kleinstein J. In-creased pregnancy rates after ultralong postoperative therapy with gonadotropin-releas-ing hormone analogs in patients with endo-metriosis. Fertil Steril 2002; 78: 757-62.
8. Niu Z, Chen Q, Sun Y, Feng Y. Long-term pituitary downregulation before frozen embryo transfer could improve pregnancy outcomes in women with adenomyosis. Gynecol Endocrinol 2013; 29: 1026-30.
9. Costello MF, Lindsay K, McNally G. The effect of adenomyosis on in vitro fertilisation and intra-cytoplasmic sperm injection treatment outcome. Eur J Obstet Gynecol Reprod Biol 2011; 158: 229-34.
10. Ren J, Sha A, Han D, Li P, Geng J, Ma C. Does prolonged pituitary down-regulation with gonadotropin-releasing hormone agonist improve the live-birth rate in in vitro fertilization treatment? Fertil Steril 2014; 102: 75-81.
11. Sunkara SK, Khan KS. Adenomyosis and female fertility: a critical review of the evidence. J Obstet Gynaecol 2012; 32: 113-6.
12. Louis LS, Saso S, Chatterjee J, Barsoum E, Al-Samarrai M. Adenomyosis and infertility. Re-prod Biomed Online 2012; 24: 586; author reply 7.
13. Ballester M, d’Argent EM, Morcel K, Belaisch-Allart J, Nisolle M, Darai E. Cumulative pregnancy rate after ICSI-IVF in patients with colorectal endometriosis: results of a multicentre study. Hum Reprod 2012; 27: 1043-9.
14. Mijatovic V, Florijn E, Halim N, Schats R, Hompes P. Adenomyosis has no adverse effects on IVF/ICSI outcomes in women with endometriosis treated with long-term pituitary down-regulation before IVF/ICSI. Eur J Obstet Gynecol Reprod Biol 2010; 151: 62-5.
15. Ramakrishnappa N, Rajamahendran R, Lin YM, Leung PC. GnRH in non-hypothalamic reproductive tissues. Anim Reprod Sci 2005; 88: 95-113.
16. van der Houwen LE, Mijatovic V, Leemhuis E, Schats R, Heymans MW, Lambalk CB, Hompes PG. Efficacy and safety of IVF/ICSI in patients with severe endometriosis after long-term pituitary down-regulation. Reprod Biomed Online 2014; 28: 39-46.
17. Khan KN, Kitajima M, Hiraki K, Fujishita A, Sekine I, Ishimaru T, Masuzaki H. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy. Hum Reprod 2010; 25: 642-53.
18. Morimoto C, Osuga Y, Yano T, Takemura Y, Harada M, Hirata T, Hirota Y, Yoshino O, Koga K, Kugu K, Taketani Y. GnRH II as a possible cytostatic regulator in the development of endometriosis. Hum Reprod 2005; 20: 3212-8.
19. Wu HM, Huang HY, Lee CL, Soong YK, Leung PC, Wang HS. Gonadotropin-releasing hormone type II (GnRH-II) agonist regulates the motility of human decidual endometrial stromal cells: possible effect on embryo implantation and pregnancy. Biol Reprod 2015; 92: 98.
20. Porcu E, Dal Prato L, Seracchioli R, Fabbri R, Longhi M, Flamigni C. Comparison between depot and standard release triptoreline in in vitro fertilization: pituitary sensitivity, luteal function, pregnancy outcome, and perinatal results. Fertil Steril 1994; 62: 126-32.
21. Elizur SE, Tulandi T. Drugs in infertility and fetal safety. Fertil Steril 2008; 89: 1595-602.
22. Lahat E, Raziel A, Friedler S, Schieber-Kazir M, Ron-El R. Long-term follow-up of children born after inadvertent administration of a gonadotrophin-releasing hormone agonist in early pregnancy. Hum Reprod 1999; 14: 2656-60.
23. Wilshire GB, Emmi AM, Gagliardi CC, Weiss G. Gonadotropin-releasing hormone agonist administration in early human pregnancy is associated with normal outcomes. Fertil Steril 1993; 60: 980-3.
24. Abu-Heija AT, Fleming R, Yates RW, Coutts JR. Pregnancy outcome following exposure to gonadotrophin-releasing hormone analogue during early pregnancy: comparisons in patients with normal or elevated luteinizing hormone. Hum Reprod 1995; 10: 3317-9.